title: Risk of thrombogenicity among nonionic radiocontrast agents.
abstract: Several contrast agents have been approved in the United States for radiographic imaging purposes. Most of the older ionic, high-osmolar contrast agents are no longer used because of their side effect profile. Therefore, newer nonionic, low or iso-osmolar contrast agents have been widely accepted as an alternative due to their improved tolerability and safety. We investigated the thrombogenicity of the 6 different nonionic radiocontrast media in terms of their platelet reactivity and noted some minor differences among them. In the 50% contrast concentration group, all of the nonionic contrast agents inhibited aggregation, whereas in the 10% contrast concentration group, all agents showed similar aggregation curves in comparison to the normal control. At 50% contrast concentration, the inhibitory effect of aggregation appeared to be related to the inhibition of calcium mobilization, which may be one of the mechanistic effects.
authors.affiliation: Division of Cardiology, Temple University School of Medicine, Philadelphia, Pennsylvania, USA.
authors.forename: Alexander
authors.initials: A
authors.lastname: Georgakis
authors.forename: Rasih Atilla
authors.initials: RA
authors.lastname: Ener
authors.forename: Jianguo
authors.initials: J
authors.lastname: Jin
authors.forename: Satya
authors.initials: S
authors.lastname: Kunapuli
authors.forename: David
authors.initials: D
authors.lastname: Fiss
authors.forename: Stephen H
authors.initials: SH
authors.lastname: Leech
authors.forename: Nelson M
authors.initials: NM
authors.lastname: Wolf
authors.forename: William A
authors.initials: WA
authors.lastname: Van Decker
mesh_terms: D001792:Blood Platelets / Q000187:drug effects; D006328:Cardiac Catheterization / Q000379:methods*; D003287:Contrast Media / Q000009:adverse effects* / Q000494:pharmacology; D003328:Coronary Thrombosis / Q000139:chemically induced* / Q000453:epidemiology* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007472:Iohexol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D007479:Iopamidol / Q000009:adverse effects / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D012307:Risk Factors; D014283:Triiodobenzoic Acids / Q000009:adverse effects / Q000494:pharmacology
chemical_list: D003287:Contrast Media; D014283:Triiodobenzoic Acids; D007472:Iohexol; C038192:iopromide; C055357:ioxilan; C044834:iodixanol; D007479:Iopamidol; C054871:ioversol